Core Viewpoint - The company, Ruizhi Pharmaceutical, announced a strategic partnership with professional investment institutions to enhance its capabilities in the innovative drug industry through a new investment fund [2] Group 1: Investment Details - The company’s wholly-owned subsidiary, Beihai Ruizhi Venture Capital Co., Ltd., will collaborate with Shenzhen Investment Control Donghai Investment Co., Ltd. and other partners to establish a new investment fund named Shenzhen Luohu Donghai Ruizhi Pharmaceutical Industry Partnership [2] - The total committed capital for the partnership is set at RMB 200 million, with Beihai Ruizhi contributing RMB 58 million, representing 29% of the total [2] - The partnership has completed the necessary registration and obtained the Private Investment Fund Registration Certificate in compliance with relevant Chinese regulations [2]

Group 1 - The A-share market has recently experienced a significant upward trend, particularly in the pharmaceutical sector, which has shown a year-to-date increase of 60.77%, outperforming the overall A-share index by 22.14% as of September 2, 2025 [1] - The performance of pharmaceutical-themed mutual funds has also been strong, with notable returns since the beginning of the year, highlighting the growing interest in this sector [1] - Zhongyin Fund's pharmaceutical-themed funds have ranked highly among peers, with Zhongyin Innovation Medical A achieving top rankings over various time frames [1][2] Group 2 - The innovative drug sector in China is expected to have significant value discovery potential, becoming a strategic industry in China's export structure and a key pillar in the global pharmaceutical industry [2] - The investment approach of Zhongyin Fund's manager, Zheng Ning, focuses on filtering out market noise and concentrating on long-term implicit returns, which is considered a sustainable investment strategy [2] Group 3 - Zhongyin Hong Kong Stock Connect Medical A, managed by Zheng Ning since December 29, 2023, has shown a net value growth rate of 70.08% in the first half of 2025, significantly outperforming its benchmark [3] - Zhongyin Innovation Medical Mixed A, also managed by Zheng Ning, has demonstrated strong performance since its inception, with a net value growth rate of 54.08% in the first half of 2025 [4][5]